'김갑성' 기자의 전체기사
-
DZYNE and HIFraser Awarded Multi-Million-Dollar (USD) Contract to…
IRVINE, Calif., Sept. 16, 2025 -- DZYNE Technologies is proud to announce a multi-million-dollar (USD) contract to supply its Dronebuster® DTIM (Detect, Track, Identify, Mitigate) Kits to the Australian Defence Force (ADF). Awarded in partnership with HIFraser, a leading Australian defense supplier, this effort falls under the ADF's LAND 156 Phase 1 program and was formally announced by The Hon. Pat Conroy MP, Minister for Defence Industry. The award represents a significant advancement in strengthening Australia's counter-uncrewed aerial systems (C-UAS) capabilities.
- 김갑성 기자
- 2025-09-16 02:00
-
LBB Specialties and Imerys Form Specialty Distribution Partners…
NORWALK, Conn., Sept. 16, 2025 -- LBB Specialties (LBBS), a leader in specialty chemicals and ingredient distribution in North America, is pleased to announce a new partnership with Imerys, a world leader in mineral-based specialties for industry. This agreement names LBBS as the preferred distributor for Imerys ImerCare® product line in Personal Care, and minerals serving the Food & Nutrition markets. The partnership extends across the United States, Canada, and Puerto Rico. Through this partnership, LBBS will support customers in the Personal Care, Life Sciences, and
- 김갑성 기자
- 2025-09-16 01:00
-
Glac Biotech Secures U.S. Food and Drug Administration GRAS…
TAIPEI, Sept. 15, 2025 -- Glac Biotech, a Taiwan-based developer of probiotics and postbiotics, announced that its core probiotic strain CP-9 (Bifidobacterium lactis CCTCC M 2014588) has been approved with Generally Recognized as Safe (GRAS) status by the U.S. Food and Drug Administration (FDA). With this notification, Glac Biotech becomes the only probiotic raw material manufacturer in Taiwan to hold multiple FDA GRAS approval, following the recognition of Lactobacillus rhamnosus MP108 in 2023. Approval Highlights CP-9's Safety and Quality According to the FDA fi
- 김갑성 기자
- 2025-09-15 22:00
-
Glac Biotech、プロバイオティクス株CP-9で米国食品医薬品局のGRAS認証を取得
[ 메디채널 김갑성 기자 ] 台北、2025年9月15日 -- Glac Biotechは、台湾を拠点とするプロバイオティクスおよびポストバイオティクスの開発企業であり、同社の中核となるプロバイオティクス株CP-9（Bifidobacterium lactis CCTCC M 2014588）が米国食品医薬品局（FDA）より「一般に安全と認められる（GRAS）」認証を取得したと発表しました。 この通知により、Glac Biotechは2023年にLactobacillus rhamnosus MP108が認定されたことに続き、台湾でFDAのGRAS認証を複数有する唯一のプロバイオティクス原料メーカーとなります。 CP-9の安全性と品質を裏付ける認証 FDAへの申請によると、CP-9は1食当たり最大10⁹コロニー形成単位（CFU）の使用が認可されており、以下のような幅広い食品および飲料製品に利用することができます。 スポーツドリンク・エナジードリンク 強化水 ボトル入り茶飲料 シリアル 乳製品および非乳製品 栄養バー キャンディ フルーツジュース 大豆・植物由来のたんぱく質製品 乳児用食品 新たに認証されたCP-9は、2023年のニュートライング
- 김갑성 기자
- 2025-09-15 22:00
-
글락바이오텍 프로바이오틱 균주 CP-9, FDA GRAS 승인 획득
[ 메디채널 김갑성 기자 ] 타이베이 2025년 9월 15일 -- 대만 기업 글락 바이오텍(Glac Biotech)이 개발한 프로바이오틱스 균주 CP-9(비피도박테리움 락티스 CCTCC M 2014588)가 FDA 승인을 획득하였다. 글락 바이오텍은 프로바이오틱스와 포스트바이오텍스 개발업체로 이번 승인 등급은 일반적으로 안전하다고 인정되는 제품(GRAS)이다. 글락 바이오텍은 이번 승인으로 2023년 락토바실러스 람노서스 MP108(Lactobacillus rhamnosus MP108) 승인에 이어 대만 프로바이오틱스 원료 제조사 중에서는 유일하게 FDA GRAS 승인을 복수로 받은 업체가 되었다. 승인은 CP-9의 안전성과 품질을 인정한 것 FDA 신고서에 따르면 CP-9는 다음과 같이 여러 식음료 제품에 1회분 당 10⁹ 콜로니 형성 단위(CFU)까지 사용 가능하다. 스포츠 및 에너지 음료 강화수 병에 담긴 차 시리얼 유제품과 비유제품 뉴트리션 바 캔디 과일 주스 콩 및 식물성 단백질 제품 유아식 이번에 승인받은 CP-9는 2023년
- 김갑성 기자
- 2025-09-15 22:00
-
HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of B…
BGE-102, an orally available, brain-penetrant NLRP3 inhibitor, was developed from a hit compound identified using HitGen's industry-leading DEL technology platform, highlighting the value of DEL to accelerate innovative drug development. The initiation of the BGE-102 Phase 1 clinical study triggers a milestone payment to HitGen. CHENGDU, China, Sept. 15, 2025 -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH), congratulates its partner BioAge Labs, Inc. ("BioAge", NASDAQ: BIOA), a clinical-stage biotechnology company base
- 김갑성 기자
- 2025-09-15 21:30
-
AMPLIFON: -42% DIRECT EMISSIONS AND -25% INDIRECT GREENHOUSE GAS…
MILAN, Sept. 15, 2025 -- Amplifon, a global leader in hearing solutions and services, is launching its climate strategy validated by the Science Based Targets Initiative (SBTi) to reduce greenhouse gas emissions and contribute to achieving the goals of the 2015 Paris Agreement to counteract climate change. The strategy, "Listening to our Planet," specifically calls for a 42% reduction in the company's direct greenhouse gas emissions (Scope 1 and 2) by 2030 compared to 2023. Over the same period, the company has committed to reducing indirect Scope 3 emissions by 25%,
- 김갑성 기자
- 2025-09-15 21:11
-
LabConnect and OmniScience to Deliver First Agentic AI Solut…
Together we're unlocking the true potential of clinical trial lab data, bringing faster insights, smarter decisions, and better outcomes. JOHNSON CITY, Tenn. and HOUSTON, Sept. 15, 2025 -- LabConnect, a leading global provider of central laboratory services today announced plans to form a strategic collaboration with OmniScience, the AI company behind Vivo, the first agentic AI control tower for clinical trials. Together, they will deliver the industry's first AI-driven solution enabling sponsors to gain intelligent, real-time insights from clinical trial lab data.
- 김갑성 기자
- 2025-09-15 21:03
-
EmeTerm Wearable Device Under Clinical Study at Ohio State We…
VANCOUVER, BC, Sept. 15, 2025 -- WAT Medical Enterprise Ltd. is proud to announce that its innovative anti-nausea wristband, EmeTerm, has made significant progress in alleviating nausea and vomiting among patients suffering from chronic gastric disorders. A clinical study currently underway at The Ohio State University Wexner Medical Center is evaluating the device's impact on individuals with moderate to severe chronic nausea, a condition that affects millions worldwide. A Growing Unmet Medical NeedChronic nausea and vomiting remain challenging to treat. According to the American Coll
- 김갑성 기자
- 2025-09-15 21:00
-
AMPLIFON: -42% DIRECT EMISSIONS AND -25% INDIRECT GREENHOUSE GAS…
MILAN, Sept. 15, 2025 -- Amplifon, a global leader in hearing solutions and services, is launching its climate strategy validated by the Science Based Targets Initiative (SBTi) to reduce greenhouse gas emissions and contribute to achieving the goals of the 2015 Paris Agreement to counteract climate change. The strategy, "Listening to our Planet," specifically calls for a 42% reduction in the company's direct greenhouse gas emissions (Scope 1 and 2) by 2030 compared to 2023. Over the same period, the company has committed to reducing indirect Scope 3 emissions by 25%,
- 김갑성 기자
- 2025-09-15 20:37
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-10-19_SUN
- Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting 15:00
- Case Report | Preliminary Clinical Data of CARsgen's Allogeneic BCMA CAR-T Product CT0596 for the Treatment of Primary Plasma Cell Leukemia 14:00
- From Wellbeing to Academics: Why HK Parents Are Hitting Pause on Kids' Social Media and Device Use 13:00
- 내면의 조화를 발견하세요: '원더풀 인도네시아 웰니스 페스티벌 2025' 개최 01:50
- 제2회 마나르 아부다비 출품 작가 명단 공개 00:48
- 중국-피지 어업 협력, 섬나라 경제 활력 끌어올리다 00:00
2025-10-18_SAT
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 10월 19일 16시 40분